NextCell Pharma company presentations
Idag, 08:45
NextCell Pharma company presentations
NextCell Pharma AB's ("NextCell" or the "Company") CEO Mathias Svahn gave a presentation at the BioStock Life Science Summit 2025 in Lund on November 13th. He will also present at Redeye Theme: Autoimmune and Inflammatory Diseases Event later today at 13:05.
The presentations can be viewed at:
BioStock Life Science Summit (on demand): https://biostock.se/2025/11/nextcell-pharma-life-science-summit-2025/
Redeye Theme: Autoimmune and Inflammatory Diseases (live): https://www.redeye.se/events/1112314/redeye-theme-autoimmune-and-inflammatory-diseases-2
Certified Adviser
The company's shares are listed on the Nasdaq First North Growth Market.
RedEye AB is assigned as Certified Adviser.
About NextCell Pharma AB
NextCell Pharma is a clinical-stage cell therapy company developing ProTrans, a patent-protected platform based on allogeneic mesenchymal stromal cells (MSCs) from umbilical cord tissue. Using a proprietary selection algorithm, ProTrans delivers optimised cell tailored to specific indications. In type 1 diabetes, a single infusion has been shown to preserve insulin production and delay disease progression for at least five years. A Phase III trial is planned to commence upon securing a commercial partner. ProTrans is also being evaluated for other autoimmune and inflammatory conditions. NextCell’s subsidiaries include Cellaviva, Scandinavia’s largest private stem cell bank, and QVance, the Nordic region’s first dedicated provider of quality services for developers of advanced therapies.
For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Tel: +46 8 735 5595
E-mail: info@nextcellpharma.com
Websites:
NextCell Pharma AB: www.nextcellpharma.com
Cellaviva Sverige: www.cellaviva.se
Cellaviva Danmark:www.cellaviva.dk
QVance AB: www.qvance.se
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
Ämnen i artikeln
NextCell Pharma company presentations
Idag, 08:45
NextCell Pharma company presentations
NextCell Pharma AB's ("NextCell" or the "Company") CEO Mathias Svahn gave a presentation at the BioStock Life Science Summit 2025 in Lund on November 13th. He will also present at Redeye Theme: Autoimmune and Inflammatory Diseases Event later today at 13:05.
The presentations can be viewed at:
BioStock Life Science Summit (on demand): https://biostock.se/2025/11/nextcell-pharma-life-science-summit-2025/
Redeye Theme: Autoimmune and Inflammatory Diseases (live): https://www.redeye.se/events/1112314/redeye-theme-autoimmune-and-inflammatory-diseases-2
Certified Adviser
The company's shares are listed on the Nasdaq First North Growth Market.
RedEye AB is assigned as Certified Adviser.
About NextCell Pharma AB
NextCell Pharma is a clinical-stage cell therapy company developing ProTrans, a patent-protected platform based on allogeneic mesenchymal stromal cells (MSCs) from umbilical cord tissue. Using a proprietary selection algorithm, ProTrans delivers optimised cell tailored to specific indications. In type 1 diabetes, a single infusion has been shown to preserve insulin production and delay disease progression for at least five years. A Phase III trial is planned to commence upon securing a commercial partner. ProTrans is also being evaluated for other autoimmune and inflammatory conditions. NextCell’s subsidiaries include Cellaviva, Scandinavia’s largest private stem cell bank, and QVance, the Nordic region’s first dedicated provider of quality services for developers of advanced therapies.
For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Tel: +46 8 735 5595
E-mail: info@nextcellpharma.com
Websites:
NextCell Pharma AB: www.nextcellpharma.com
Cellaviva Sverige: www.cellaviva.se
Cellaviva Danmark:www.cellaviva.dk
QVance AB: www.qvance.se
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
Ämnen i artikeln
Analyser
Intellego
Techbolagen
Bolånen
Analyser
Mest läst
Intellego
Techbolagen
Bolånen
Marknadsöversikt
1 DAG %
Senast
1 mån
